Summary

Global Neglected Tropical Diseases Diagnosis Market was valued at USD 6.20 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.09% through 2030. Neglected Tropical Diseases (NTDs) refer to a group of infectious diseases that primarily affect populations in low-income and tropical or subtropical regions of the world. These diseases are characterized by their prevalence in marginalized and impoverished communities, often lacking access to adequate healthcare, clean water, sanitation, and preventive measures. NTDs disproportionately affect the world's poorest and most marginalized populations, particularly those living in rural or urban slum areas. These communities often lack access to basic healthcare services. NTDs are caused by a variety of infectious agents, including bacteria, viruses, parasites, and protozoa. The transmission of these diseases is often linked to environmental factors and vectors, such as mosquitoes or flies. NTD advocacy groups and awareness campaigns have played a significant role in increasing public and political awareness about these diseases. This has resulted in greater support for diagnosis and treatment efforts.
Key Market Drivers
Advancements in Diagnostics
Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) have revolutionized NTDs diagnosis. They allow for the detection of the genetic material of pathogens with high sensitivity and specificity. Molecular diagnostics are particularly useful for diseases like Chagas disease and Leishmaniasis. For instance, according to a 2024 NCBI article, advancements in artificial intelligence are enhancing medical computer-aided diagnosis, improving accuracy, efficiency, and early disease detection for better patient outcomes.
Also, in May 2022, medical technology company Anitoa Systems launched a portable RT-PCR test for dengue virus detection, expanding its Maverick RT-PCR device line. This multiplex test detects multiple target genes linked to severe dengue, ensuring early and accurate diagnosis. Point-of-Care Testing (POCT) devices have been developed for various NTDs, enabling rapid and on-site diagnosis. These portable devices are especially valuable in remote and resource-limited settings where access to centralized laboratories is limited. Examples include rapid diagnostic tests for malaria and dengue. Serological tests detect specific antibodies produced by the immune system in response to infection. Advances in serological assays have improved their accuracy and made them more widely available for diagnosing diseases like schistosomiasis and lymphatic filariasis. Some NTDs can be diagnosed by detecting specific antigens produced by the pathogens. Antigen detection tests are valuable for diseases like African sleeping sickness and urinary schistosomiasis.
Key Market Challenges
Lack of Sensitive and Specific Tests
Many NTDs share symptoms with other diseases or have multiple stages, making accurate diagnosis difficult. When sensitive and specific tests are lacking, there's a higher risk of misdiagnosis or underdiagnosis, leading to delayed or inadequate treatment. Accurate diagnosis is essential for determining the appropriate treatment regimen. Without sensitive and specific tests, healthcare providers may resort to empirical treatment, which can result in unnecessary healthcare costs and potential drug resistance. NTDs control and elimination programs rely on accurate data to target affected populations effectively. Inaccurate diagnosis can lead to misallocation of resources, potentially slowing down progress in controlling these diseases. For tracking the prevalence and distribution of NTDs, sensitive and specific tests are crucial. Inaccurate diagnostic tools can lead to inaccurate disease surveillance data, hindering the ability to detect outbreaks or changes in disease patterns. Diagnostic tools are fundamental in research efforts related to NTDs, including drug and vaccine development. Insensitive or nonspecific tests can slow down the research process and hinder the identification of potential therapeutic targets. Patients may undergo multiple tests, sometimes invasive, to confirm an NTD diagnosis due to the lack of definitive tests. This can result in a physical and psychological burden on affected individuals. Limited healthcare resources in endemic regions should be used efficiently. Sensitive and specific tests are essential for targeting interventions to those who need them most, thereby optimizing resource allocation.
Key Market Trends
Focus on Early Detection
Early detection allows for prompt initiation of treatment, which can lead to better outcomes for patients. For many NTDs, early treatment can prevent disease progression and complications. Early diagnosis and treatment can help break the cycle of transmission of NTDs. By identifying and treating infected individuals early, there is a reduced risk of spreading the disease to others through vectors or direct contact. Some NTDs, such as lymphatic filariasis and leprosy, can cause disabling conditions if not treated early. Early detection and intervention can prevent or reduce disability and improve the quality of life for affected individuals. Early detection can be cost-effective in the long run. It reduces the need for more extensive and expensive treatments that may be required if NTDs are diagnosed at a later stage. Timely diagnosis contributes to the success of NTDs control and elimination programs. Early detection allows for more targeted and efficient interventions, which can accelerate progress toward achieving disease control goals. Some NTDs are associated with social stigma and discrimination. Early diagnosis and treatment can help individuals avoid the social consequences of living with untreated NTDs. Advances in point-of-care diagnostic technologies make it possible to diagnose NTDs quickly and accurately in resource-limited settings, enabling immediate treatment and reducing the need for follow-up visits.
Key Market Players
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• DiaSys Diagnostics Systems GmbH
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Oscar Medicare Pvt Ltd.
• Coris BioConcept
Report Scope:
In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Neglected Tropical Diseases Diagnosis Market, By Disease:
o Dengue
o Chikungunya
o Rabies
o Buruli Ulcer
o Yaws
o Lymphatic Filariasis
o Taeniasis/Cysticercosis
o Dracunculiasis
o Others
• Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:
o Conventional
o Molecular/Modern
• Neglected Tropical Diseases Diagnosis Market, By Service Type:
o Centralized Service
o POC Service
• Neglected Tropical Diseases Diagnosis Market, By End-Use:
o Clinical Labs
o Hospital/Clinics
o Home Healthcare
• Neglected Tropical Diseases Diagnosis Market, By region:
o North America
§ United States
§ Canada
§ Mexico
o Asia-Pacific
§ China
§ India
§ South Korea
§ Australia
§ Japan
o Europe
§ Germany
§ France
§ United Kingdom
§ Spain
§ Italy
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.
Available Customizations:
Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Neglected Tropical Diseases Diagnosis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
5.2.3. By Service Type (Centralized Service, POC Service)
5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Diagnostic Method
6.2.3. By Service Type
6.2.4. By End Use
6.2.5. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease
6.3.1.2.2. By Diagnostic Method
6.3.1.2.3. By Service Type
6.3.1.2.4. By End Use
6.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease
6.3.2.2.2. By Diagnostic Method
6.3.2.2.3. By Service Type
6.3.2.2.4. By End Use
6.3.3. Australia Neglected Tropical Diseases Diagnosis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease
6.3.3.2.2. By Diagnostic Method
6.3.3.2.3. By Service Type
6.3.3.2.4. By End Use
6.3.4. Japan Neglected Tropical Diseases Diagnosis Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Disease
6.3.4.2.2. By Diagnostic Method
6.3.4.2.3. By Service Type
6.3.4.2.4. By End Use
6.3.5. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Disease
6.3.5.2.2. By Diagnostic Method
6.3.5.2.3. By Service Type
6.3.5.2.4. By End Use
7. Europe Neglected Tropical Diseases Diagnosis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Diagnostic Method
7.2.3. By Service Type
7.2.4. By End Use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Neglected Tropical Diseases Diagnosis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease
7.3.1.2.2. By Diagnostic Method
7.3.1.2.3. By Service Type
7.3.1.2.4. By End Use
7.3.2. Germany Neglected Tropical Diseases Diagnosis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease
7.3.2.2.2. By Diagnostic Method
7.3.2.2.3. By Service Type
7.3.2.2.4. By End Use
7.3.3. Spain Neglected Tropical Diseases Diagnosis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease
7.3.3.2.2. By Diagnostic Method
7.3.3.2.3. By Service Type
7.3.3.2.4. By End Use
7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease
7.3.4.2.2. By Diagnostic Method
7.3.4.2.3. By Service Type
7.3.4.2.4. By End Use
7.3.5. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease
7.3.5.2.2. By Diagnostic Method
7.3.5.2.3. By Service Type
7.3.5.2.4. By End Use
8. North America Neglected Tropical Diseases Diagnosis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Diagnostic Method
8.2.3. By Service Type
8.2.4. By End Use
8.2.5. By Country
8.3. North America: Country Analysis
8.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease
8.3.1.2.2. By Diagnostic Method
8.3.1.2.3. By Service Type
8.3.1.2.4. By End Use
8.3.2. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease
8.3.2.2.2. By Diagnostic Method
8.3.2.2.3. By Service Type
8.3.2.2.4. By End Use
8.3.3. Canada Neglected Tropical Diseases Diagnosis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease
8.3.3.2.2. By Diagnostic Method
8.3.3.2.3. By Service Type
8.3.3.2.4. By End Use
9. South America Neglected Tropical Diseases Diagnosis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Diagnostic Method
9.2.3. By Service Type
9.2.4. By End Use
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease
9.3.1.2.2. By Diagnostic Method
9.3.1.2.3. By Service Type
9.3.1.2.4. By End Use
9.3.2. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease
9.3.2.2.2. By Diagnostic Method
9.3.2.2.3. By Service Type
9.3.2.2.4. By End Use
9.3.3. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease
9.3.3.2.2. By Diagnostic Method
9.3.3.2.3. By Service Type
9.3.3.2.4. By End Use
10. Middle East and Africa Neglected Tropical Diseases Diagnosis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease
10.2.2. By Diagnostic Method
10.2.3. By Service Type
10.2.4. By End Use
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease
10.3.1.2.2. By Diagnostic Method
10.3.1.2.3. By Service Type
10.3.1.2.4. By End Use
10.3.2. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease
10.3.2.2.2. By Diagnostic Method
10.3.2.2.3. By Service Type
10.3.2.2.4. By End Use
10.3.3. UAE Neglected Tropical Diseases Diagnosis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease
10.3.3.2.2. By Diagnostic Method
10.3.3.2.3. By Service Type
10.3.3.2.4. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. F. Hoffmann-La Roche Ltd
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Abbott Laboratories Inc.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Thermo Fisher Scientific Inc.
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. ZeptoMetrix LLC
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. InBios International, Inc.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Genome Diagnostics Pvt. Ltd.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Omega Diagnostics Group Plc
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Coris Bioconcept
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Oscar medicare Pvt Ltd.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10. DiaSys Diagnostics Systems GmbH
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer